Seaport Therapeutics, Inc. SPTX
Set alert
20.01 USD +0.41 +2.09%
At close · Nov 2
20.01 0.00 0.00%
After hours · Nov 2, 4:33 PM ET
19.27 Day range 21.07
14.85 52-week range 28.38
- YTD
- +0.86%
- 1 year
- +0.86%
- Open
- 19.68
- Prev close
- 19.60
- Mkt cap
- 1.07B
- Vol
- 527.90K
- Avg vol
- 209.79K
- EPS
- -5.97
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.27
- High
- 21.07
- Forward P/E
- -7.94
- Beta
- 0.00
- Short ratio
- 12.17
- Inst. own
- 71.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 21.16
- 200-d avg
- 20.13
- 1y target
- 37.00
3M chart
Events in this range
- Aug 3, 2026Earnings: -1.78; estimate -0.62039; surprise -186.92%
- Aug 20, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 26, 2026Rating: Jones Trading · — → Buy
- Sep 10, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 25, 2026Rating: Raymond James · — → Strong Buy
- Oct 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 14, 2026Rating: Canaccord Genuity · — → Buy
- Nov 2, 2026Earnings: —; estimate -0.58; surprise —%
Signals (11)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Aug 26, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
Key statistics
- Market cap
- 1.07B
- Enterprise value
- 780.91M
- Trailing P/E
- 0.00
- Forward P/E
- -7.94
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.53
- EPS (TTM)
- -5.81
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 273.31M
- Total debt
- 5.02M
- Return on equity
- 0.00%
- Shares outstanding
- 53.53M
- Short % of float
- 7.30%
- 50-day average
- 21.16
- 200-day average
- 20.13
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 37.00 +84.9% upside
Now 20.01
- Target (low)
- 28.00
- Target (mean)
- 37.00
- Target (high)
- 50.00
Ratings (0m) 9 8 buy · 1 hold · 0 sell
- Strong buy1
- Buy7
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate -0.59584.
Financials — quick view
SPTX Revenue — quarterly 0
SPTX Net income — quarterly -62.60M
SPTX EPS — quarterly -1.78
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | -0.58 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | -0.62039 | -1.78 | -1.16 | -186.92% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | Canaccord Genuity | init | — | Buy |
| Oct 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 25, 2026 | Raymond James | init | — | Strong Buy |
| Sep 10, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 26, 2026 | Jones Trading | init | — | Buy |
| Aug 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- seaporttx.com
News
- Seaport Therapeutics Q3 EPS $(0.49) Beats $(0.58) Estimate
- Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
- Seaport Therapeutics: Borrowed Efficacy, Engineered Safety, And A Post-IPO Discount
- This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28
- PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
- PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
- Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
- Seaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13
- Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Your note
Sign in to keep a note on SPTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE PARTNERS XII, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 3, 2026 | 0 |
| CHEN MICHAEL CUNYUAN PH.D. | Officer | Conversion of Exercise of derivative security | May 3, 2026 | 3,351 |
| GLADSTEIN LANA J.D. | General Counsel | Conversion of Exercise of derivative security | May 3, 2026 | 33,515 |
| HEALY JAMES I | Director | Conversion of Exercise of derivative security | May 3, 2026 | 0 |
| HOMBACH ROBERT J. CPA | Director | Purchase | Jun 21, 2026 | 0 |
| LOEBEL ANTONY M.D. | Officer | Conversion of Exercise of derivative security | May 3, 2026 | 20,109 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Arch Venture Management, Llc | 11.76% | 6,294,951 | 125.96M | Jun 29, 2026 |
| General Atlantic, L.P. | 11.40% | 6,101,582 | 122.09M | Jun 29, 2026 |
| Sofinnova Investments, Inc. | 6.66% | 3,564,871 | 71.33M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.07% | 2,178,642 | 43.59M | Jun 29, 2026 |
| Trv Gp VI, LLC | 3.85% | 2,061,222 | 41.25M | Jun 29, 2026 |
| Canada Pension Plan Investment Board | 3.69% | 1,975,791 | 39.54M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 1.57% | 840,931 | 16.83M | Jun 29, 2026 |
| Prudential Sector Funds, Inc.-PGIM Jennison Health Sciences Fund | 0.82% | 438,754 | 8.78M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.80% | 426,371 | 8.53M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.79% | 424,190 | 8.49M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.66% | 355,159 | 7.11M | Sep 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.56% | 299,319 | 5.99M | Jun 29, 2026 |